Panbela Therapeutics, Inc. Completes Enrollment in Its Phase 1b Trial Investigating SBP-101 Combination Therapy for First-Line Metastatic Pancreatic Cancer

Panbela Therapeutics, Inc., formerly Sun Biopharma, a UF startup and clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has completed patient enrollment in its Phase 1 trial evaluating the safety and tolerability of SBP-101 when used in combination with standard of care agents gemcitabine and nab-paclitaxel for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA).

FLIR Systems Acquires UF Startup Altavian, Inc.

FLIR Systems, Inc., a company specializing in the design and production of thermal imaging cameras, components and imaging sensors, announced that it has acquired UF startup Altavian, Inc., a privately-held manufacturer of small unmanned aerial systems (sUAS) for defense and public safety customers.

AGTC Goes Mobile to Avoid Clinical Trial Chaos

When leaders of UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC realized how disruptive COVID-19 might become, they developed a plan—several of them, in fact—to minimize clinical chaos.

Sun BioPharma, Inc. Changes Name to Panbela Therapeutics Inc.

UF startup Sun BioPharma, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has announced the change of its corporate name to Panbela Therapeutics, Inc. effective December 2, 2020.

AbFero to Receive € 2M Eurostars Funding for Parkinson’s Disease Therapy

AbFero Ltd., a subsidiary of UF startup AbFero Pharmaceuticals, Inc., a privately-held clinical-stage pharmaceutical company dedicated to treating diseases of iron overload, announced the funding of approximately € 2M from EUREKA Eurostars for the development of iron-chelating compounds including their lead agent, SP-420, as a disease-modifying therapy for Parkinson’s disease.